AzTrials
AzTrials

OsteoarthritisPhase 3NCT01089725

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

A Phase 3 study testing Tanezumab SC and Tanezumab IV in people with Osteoarthritis and Arthritis, run by Pfizer at 91 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Osteoarthritis, Arthritis, Pain
What is being tested?
Tanezumab SC and Tanezumab IV
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
385 participants
Where
91 sitesUnited States
Study dates
30 Mar 2010to 18 Feb 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
  • 18 years of age or greater
  • Two methods of birth control one of which must be barrier if of childbearing potential
  • Willing to discontinue pain medication except as permitted per protocol

Who cannot join

  • Pregnancy or wishing to be pregnant during the course of the study, lactating women
  • Body Mass Index (BMI) greater than 39
  • Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
  • Previous exposure to a Nerve Growth Factor (NGF) antibody

Trial locations and contacts

91 sites in 1 country.

91 sites in 1 country

United States91 sites
  • Advanced Clinical Research Institute

    Anaheim, California, 92801

  • West Coast Radiology Center

    Anaheim, California, 92801

  • Ann Arbor Clinical Reserch

    Ann Arbor, Michigan, 48103

  • FutureSearch Trials of Neurology

    Austin, Texas, 78731

  • Tekton Research, Inc.

    Austin, Texas, 78745

  • Tekton Research, Inc

    Austin, Texas, 78745

  • Billings Clinic Infusion Center

    Billings, Montana, 59101

  • Billings Clinic Research Center

    Billings, Montana, 59101

  • Sonoma Clinical Research, LLC.

    Boise, Idaho, 83702

  • Sonora Clinical Research

    Boise, Idaho, 83702

  • Beacon Clinical Research, LLC

    Brockton, Massachusetts, 02301

  • Providence Clinical Research

    Burbank, California, 91505

  • PMG Research of Charlotte

    Charlotte, North Carolina, 28209-3734

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911

  • Apex Medical Research, AMR, Inc.

    Chicago, Illinois, 60616

  • Community Research

    Cincinnati, Ohio, 45245

  • Sterling Research Group, Ltd.

    Cincinnati, Ohio, 45246

  • Mountain State Clinical Research

    Clarksburg, West Virginia, 26301

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida, 33756

  • Nature Coast Clinical Research

    Crystal River, Florida, 34429

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Colorado Hematology

    Englewood, Colorado, 80110

  • Colorado Orthopedic Consultants, P.C.

    Englewood, Colorado, 80110

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida, 32003

  • Arthritis Treatment Center

    Frederick, Maryland, 21702

  • Valley Research

    Fresno, California, 93720

  • Greensboro Imaging

    Greensboro, North Carolina, 27407

  • Pharmquest

    Greensboro, North Carolina, 27408

  • Arthritis Associates, PLLC

    Hattiesburg, Mississippi, 39402

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814

  • Westbury Medical Clinic

    Houston, Texas, 77005

  • Asif Cochinwala, MD, P.A.

    Houston, Texas, 77008

  • Accurate Clinical Research

    Houston, Texas, 77034

  • Mercury Clinical Research

    Houston, Texas, 77036

  • Pioneer Research Solutions, Inc

    Houston, Texas, 77036

  • Clinical Trial Network

    Houston, Texas, 77074

  • Houston Institute for Clinical Research

    Houston, Texas, 77074

  • Little York Medical Center

    Houston, Texas, 77093

  • Westside Center for Clinical Research

    Jacksonville, Florida, 32205

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216

  • SoFHA Clinical Research

    Johnson City, Tennessee, 37604

  • Internist Associates of Texas

    Kingwood, Texas, 77339

  • Allergy and Rheumatology Medical Clinic, Inc.

    La Jolla, California, 92037-1233

  • Triwest Research Associates

    La Mesa, California, 91942

  • BayCare Outpatient Imaging at Bardmoor

    Largo, Florida, 33777

  • G. Timothy Kelly, MD

    Las Vegas, Nevada, 89128

  • Lebanon Internal Medicine Associates

    Lebanon, Pennsylvania, 17042

  • Bluegrass Community Research, Inc.

    Lexington, Kentucky, 40504

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516

  • Novara Clinical Research

    Mesa, Arizona, 85206

  • BenchMark Research

    Metairie, Louisiana, 70006

  • Vaughn H. Mancha, Jr., MD, PC

    Montgomery, Alabama, 36117

  • Coastal Carolina Research Center

    Mt. Pleasant, South Carolina, 29464

  • Accurate Clinical Research Inc

    Nassau Bay, Texas, 77058

  • Synergy Clinical Research Center

    National City, California, 91950

  • LION Research

    Norman, Oklahoma, 73069

  • McBride Clinic

    Norman, Oklahoma, 73072

  • Health Research Institute

    Oklahoma City, Oklahoma, 73109

  • Midwest Minor Medical

    Omaha, Nebraska, 68114

  • Quality Clinical Research, Inc.

    Omaha, Nebraska, 68114

  • Midwest Minor Medical

    Omaha, Nebraska, 68127

  • Midwest Minor Medical

    Omaha, Nebraska, 68144

  • Sunshine Research Center

    Opa-locka, Florida, 33054

  • Founders Research Corporation

    Philadelphia, Pennsylvania, 19152

  • Redpoint Research

    Phoenix, Arizona, 85029

  • DMI Research, Inc.

    Pinellas Park, Florida, 33782

  • Clinical Investigations of Texas, LLC

    Plano, Texas, 75075

  • Wake Internal Medicine Consultants, Inc.

    Raleigh, North Carolina, 27612

  • Wake Research Associates, LLC

    Raleigh, North Carolina, 27612

  • Health Concepts

    Rapid City, South Dakota, 57702

  • Hypothe Test, LLC

    Roanoke, Virginia, 24018

  • Andrew Porges, MD, PC

    Roslyn, New York, 11576

  • Benchmark Research

    Sacramento, California, 95816

  • Benchmark Research

    San Angelo, Texas, 76904

  • Probe Clinical Research Corp.

    Santa Ana, California, 92701

  • Trinity Clinical Trials

    Santa Ana, California, 92701

  • St. Petersburg Arthritis Center

    St. Petersburg, Florida, 33710

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905

  • Pioneer Research Solutions, Inc

    Sugar Land, Texas, 77479

  • Troy Internal Medicine, PC

    Troy, Michigan, 48098

  • FMC Clinical Trials

    Upland, California, 91786

  • Office of Cynthia Morgan, MD

    Washington D.C., District of Columbia, 20003

  • Advanced Clinical Research

    West Jordan, Utah, 84088

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Professional Research Network of Kansas, LLC

    Wichita, Kansas, 67203

  • Wichita Clinic PA

    Wichita, Kansas, 67208

  • Grayline Clinical Drug Trials

    Wichita Falls, Texas, 76309

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189

  • North Georgia Internal Medicine

    Woodstock, Georgia, 30189

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01610

  • Clinical Research Center of Reading, LLP

    Wyomissing, Pennsylvania, 19610

Other trials in United States

About this study

Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE.

This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.

Read the detailed description

This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.

Being tested
Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
Keywords
safety, efficacy, parallel group, double-blind, multicenter, injection, infusion, osteoarthritis, bridging, subcutaneous, intravenous, tanezumab
Medical subject headings
Osteoarthritis, Arthritis, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo IVBiological

    1 ml of placebo administered SC and IV once every 8 weeks.

  • Placebo SCBiological

    1 ml of placebo administered SC and IV once every 8 weeks.

  • Tanezumab SCBiological

    1 ml tanezumab injection SC administered every 8 weeks

  • Placebo IVBiological

    1 ml placebo administered IV every 8 weeks

  • Tanezumab SCBiological

    1 ml tanezumab injection SC administered every 8 weeks

  • Placebo IVBiological

    1ml placebo administered IV every 8 weeks

  • Tanezumab SCBiological

    1 ml tanezumab injection SC administered every 8 weeks

  • Placebo IVBiological

    1ml placebo administered IV every 8 weeks

  • Tanezumab IVBiological

    1 ml tanezumab injection IV administered every 8 weeks

  • Placebo SCBiological

    1ml placebo administered SC every 8 weeks

Study groups in NCT01089725
Study groupRoleWhat they receive
PlaceboPlacebo comparatorNot described
Receives: Biological: Placebo IV; Biological: Placebo SC
2.5 mg tanezumab SC and placebo IVExperimentalNot described
Receives: Biological: Tanezumab SC; Biological: Placebo IV
5 mg tanezumab SC and placebo IVExperimentalNot described
Receives: Biological: Tanezumab SC; Biological: Placebo IV
10 mg tanezumab SC and placebo IVExperimentalNot described
Receives: Biological: Tanezumab SC; Biological: Placebo IV
10 mg tanezumab IVExperimentalNot described
Receives: Biological: Tanezumab IV; Biological: Placebo SC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16

    The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.

    Measured: Baseline, Week 16

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16

    The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.

    Measured: Baseline, Week 16

  3. Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis Score at Week 16

    Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.

    Measured: Baseline, Week 16

Secondary outcomes (18)
  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 1, 2, 4, 8, and 12

    The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.

    Measured: Baseline, Weeks 1, 2, 4, 8, and 12

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 1, 2, 4, 8, and 12

    The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.

    Measured: Baseline, Weeks 1, 2, 4, 8, and 12

  3. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 1, 2, 4, 8, and 12

    Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.

    Measured: Baseline, Weeks 1, 2, 4, 8, and 12

  4. Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response

    The OMERACT-OARSI responder index is based on 3 parameters. OMERACT-OARSI response: greater than or equal to (>=) 50 percent (%) improvement from baseline and absolute change from baseline of >=2 units at week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score range: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score range: 0-10, higher score=higher pain/difficulty).

    Measured: Weeks 1, 2, 4, 8, 12, and 16

  5. Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

    The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.

    Measured: Weeks 1, 2, 4, 8, 12, and 16

  6. Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale Score at Weeks 1, 2, 4, 8, 12, and 16

    The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.

    Measured: Weeks 1, 2, 4, 8, 12, 16

  7. Number of Participants With Improvement of at Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis

    Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.

    Measured: Weeks 1, 2, 4, 8, 12, and 16

  8. Change From Baseline in Average Pain Score in the Index Knee at Weeks 1, 2, 4, 8, 12 and 16

    Participants assessed average osteoarthritis pain in their knee in the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Higher score indicated greater pain. Baseline score was calculated as the mean of the scores over the 3 days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores within each study week.

    Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16

  9. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 1, 2, 4, 8, 12, and 16

    The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 2 individual questions scored on NRS of 0 to 10, with higher scores indicating more stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate more stiffness. Stiffness is defined as a sensation of decreased ease in movement of the knee.

    Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16

  10. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 1, 2, 4, 8, 12, and 16

    WOMAC: self-administered, disease-specific 24-item questionnaire, which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores. WOMAC pain, physical function and stiffness subscale and average score ranges from 0 to 10, where higher score indicates worse response.

    Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16

  11. Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 1, 2, 4, 8, 12, and 16

    Participants answered: "How much pain have you had when walking on a flat surface?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.

    Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16

  12. Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 1, 2, 4, 8, 12, and 16

    Participants answered: "How much pain have you had when going up or down stairs?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.

    Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16

  13. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 16

    SF-36v2 is a standardized self-administered survey evaluating 8 aspects/domains of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The total score for each domain is scaled 0-100 (100 = highest level of functioning).

    Measured: Baseline, Week 16

  14. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 16

    SF-36v2: standardized self-administered survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100 (100=highest level of functioning). For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.

    Measured: Baseline, Week 16

  15. Time to Discontinuation Due to Lack of Efficacy

    Median time to discontinuation due to lack of efficacy for participants who discontinued due to lack of efficacy was reported.

    Measured: Baseline up to Week 24

  16. Percentage of Participants Who Used Rescue Medication

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Incidence of rescue medication use is calculated as any use of rescue medication during the study week in question.

    Measured: Weeks 1, 2, 4, 8, 12, and 16

  17. Duration of Rescue Medication Use

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Duration of rescue medication use is calculated as the number of study days per week when any rescue medication was taken.

    Measured: Weeks 1, 2, 4, 8, 12, and 16

  18. Amount of Rescue Medication Taken

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. The amount of rescue medication taken is the total dose (in mg) of acetaminophen rescue medication over the study week in question.

    Measured: Weeks 1, 2, 4, 8, 12, and 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2010 (estimated)
  2. Study start30 Mar 2010
  3. Primary completion8 Nov 2010
  4. Study completion18 Feb 2011

Why it stopped: See termination reason in detailed description.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
385 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01089725
Sponsor's protocol ID
A4091027
Other IDs
SC/IV OA STUDY
Status last verified
Feb 2021
First submitted
11 Mar 2010
Last updated
5 May 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.

    PubMed 37460782
  • Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021 Dec;75(12):e14975. doi: 10.1111/ijcp.14975. Epub 2021 Oct 21.

    PubMed 34626502
  • Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.

    PubMed 33973384
  • Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

    PubMed 30936738

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tanezumab SC and Tanezumab IV in people with Osteoarthritis and Arthritis, run by Pfizer at 91 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 91 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 (time frame: Baseline, Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01089725, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in